Thanks to the improved restaging accuracy and enhanced target delineation, PSMA-PET holds potential to significantly impact the management of recurrent prostate cancer, allowing for more effective imaging-guided treatments [2,9]. The gene discussed is FOLH1; the disease is prostate carcinoma.